<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305849</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-RAJ4</org_study_id>
    <nct_id>NCT02305849</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment</brief_title>
  <official_title>Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to verify the efficacy of ASP015K versus placebo&#xD;
      administrated in combination with methotrexate (MTX) over placebo in terms of efficacy in&#xD;
      participants with rheumatoid arthritis (RA) who had an inadequate response to MTX&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a multi-center, randomized, placebo-controlled, double-blind, parallel-group,&#xD;
      confirmatory study to evaluate the efficacy and safety of ASP015K (100 and 150 mg/day)&#xD;
      administered in combination with MTX in participants with RA who had an inadequate response&#xD;
      to MTX.&#xD;
&#xD;
      Participants orally received ASP015K 100 mg, ASP015K 150 mg or placebo once daily (QD) in&#xD;
      combination with MTX after breakfast for 52 weeks.&#xD;
&#xD;
      At Week 12, inadequate responders in the placebo group, as determined by a &lt; 20% improvement&#xD;
      from baseline (i.e., treatment initiation day) in tender or painful joint count (TJC) and&#xD;
      swollen joint count (SJC), were switched to either ASP015K 100 mg or ASP015K 150 mg, and the&#xD;
      dosage was maintained until the end of treatment (EOT). In addition, participants who&#xD;
      received placebo at Week 28 were switched to either ASP015K 100 mg or ASP015K 150 mg, and the&#xD;
      dosage was maintained until the EOT.&#xD;
&#xD;
      The ASP015K dose that was started for placebo group participants at Week 12 or Week 28 was&#xD;
      randomly chosen at baseline. The dose was switched under the blinded condition.&#xD;
&#xD;
      Participants who completed this study were eligible for participation in the open-label&#xD;
      extension study (015K-CL-RAJ2). Participants made a follow-up visit after the week 52 visit&#xD;
      if they did not enroll into the extension study on the day of the week 52 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2014</start_date>
  <completion_date type="Actual">November 28, 2017</completion_date>
  <primary_completion_date type="Actual">June 20, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12</measure>
    <time_frame>Baseline and week 12/Early termination (ET)</time_frame>
    <description>ACR20 response: greater than and equal to (≥) 20 percent (%) improvement in tender and swollen joint count; and ≥ 20% improvement in at least 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in mTSS at Week 28</measure>
    <time_frame>Baseline and week 28/ET</time_frame>
    <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change from baseline was calculated as score at week 28 (ET) minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an ACR20-CRP Response Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>ACR20 response:≥ 20% improvement in tender and swollen joint count; and ≥ 20% improvement in at least 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. EOT was defined as end of treatment i.e, either early termination or week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an ACR50-CRP Response at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>ACR50 response: ≥50% improvement in tender and swollen joint counts and 50% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an ACR50-CRP Response Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>ACR50 response: ≥50% improvement in tender and swollen joint counts and 50% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an ACR70-CRP Response at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>ACR70 response: ≥ 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an ACR70-CRP Response Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>ACR70 response: ≥ 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in mTSS at Week 52</measure>
    <time_frame>Baseline and week 52/ET</time_frame>
    <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change from baseline was calculated as score at week 52 (ET) minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in JSN Score at Week 28 and Week 52</measure>
    <time_frame>Baseline and weeks 28/ET and 52/ET</time_frame>
    <description>JSN was defined as narrowing in joint space width over the course of the study. The JSN score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. JSN, including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. Higher scores indicate greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erosion Score at Week 28 and Week 52</measure>
    <time_frame>Baseline and weeks 28/ET and 52/ET</time_frame>
    <description>The joint erosion score was a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint in the hand is scored from 0-5 and each joint in the foot is scored from 0-10. The score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet. By summing these score, the range of total erosion score is 0-280. Higher erosion score indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Change From Baseline in mTSS &lt;= 0.5 at Week 28 and Week 52</measure>
    <time_frame>Baseline and week 28/ET and 52/ET</time_frame>
    <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score (DAS) 28-CRP at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-CRP Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-ESR at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-ESR Score Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC (68 Joints) at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the following 68 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher TJC indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TJC (68 Joints) Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the following 68 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher TJC indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC (66 Joints) at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the following 66 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher SJC indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SJC (66 Joints) Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the following 66 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher SJC indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-CRP Score &lt; 2.6 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-CRP Score &lt; 2.6 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-ESR Score &lt; 2.6 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-ESR Score &lt; 2.6 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-CRP Score &lt;= 3.2 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-CRP Score &lt;= 3.2 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-ESR Score &lt;= 3.2 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28-ESR Score &lt;= 3.2 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CRP at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>Higher CRP indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CRP Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>Higher CRP indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ESR at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>Higher ESR indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ESR Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>Higher ESR indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a European League Against Rheumatism (EULAR) Good Response Using DAS28-CRP at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a EULAR Good Response Using DAS28-CRP Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a EULAR Good Response Using DAS28-ESR at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in the outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a EULAR Good Response Using DAS28-ESR Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a EULAR Good or Moderate Response Using DAS28-ESR at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a EULAR Good or Moderate Response Using DAS28-ESR Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR / EULAR Remission at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤1, CRP ≤1 mg/dL, and participant's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR / EULAR Remission Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤1, CRP ≤1 mg/dL, and participant's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Remission &lt;=3.3 at Week 12</measure>
    <time_frame>Week 12/ET</time_frame>
    <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SDAI Remission Score &lt;=3.3 Through Week 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDAI Score at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description: SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDAI Score Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description: SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PGA at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PGA Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The investigator assessed the participants disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGA at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGA Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGAP at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicated greater activity pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGAP Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicated greater activity pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Withdrew Due to Lack of Efficacy</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Participants who discontinued due to lack of efficacy have been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
    <description>Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form Health Survey - 36 Questions, Version 2 (SF-36v2) Physical Component Summary Score at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Physical Component Summary Score Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Mental Component Summary Score at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Mental Component Summary Score Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Role/Social Component Summary Score at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36v2 Role/Social Component Summary Score Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
    <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Percent Work Time Missed at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent work time missed due to problem was calculated as Q2/(Q2+Q4). Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Work Time Missed Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent work time missed due to problem was calculated as Q2/(Q2+Q4). Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Impairment While Working at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent impairment while working due to problem was calculated as Q5/10. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Impairment While Working Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent impairment while working due to problem was calculates as Q5/10. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Overall Work Impairment at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent overall work impairment due to problem was calculated as Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)]. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Overall Work Impairment Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent overall work impairment due to problem was calculated as Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)]. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Activity Impairment at Week 12</measure>
    <time_frame>Baseline and week 12/ET</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent activity impairment due to problem was calculated as Q6/10. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WPAI Percent Activity Impairment Through Week 52</measure>
    <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
    <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent activity impairment due to problem was calculated as Q6/10. Negative values indicate improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) During the First 12 Weeks</measure>
    <time_frame>Week 0 to week 12</time_frame>
    <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs From Week 12 to Week 28</measure>
    <time_frame>Week 12 to week 28</time_frame>
    <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on NCI-CTCAE, AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAEs From Week 28 to Week 52</measure>
    <time_frame>Week 28 to week 52, plus 28 days after the week 52 visit for participants who did not enroll in the extension study</time_frame>
    <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">519</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Peficitinib 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peficitinib 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peficitinib</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Peficitinib 100 mg</arm_group_label>
    <arm_group_label>Peficitinib 150 mg</arm_group_label>
    <other_name>ASP015K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral tablet/capsule</description>
    <arm_group_label>Peficitinib 100 mg</arm_group_label>
    <arm_group_label>Peficitinib 150 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has RA of &lt; 10 years duration at baseline that was diagnosed according to the&#xD;
             1987 American College of Rheumatology (ACR) criteria or the 2010 American College of&#xD;
             Rheumatology/European League against Rheumatism (ACR/EULAR) criteria&#xD;
&#xD;
          -  Subject who did not receive the following drugs, or received the drugs with stable&#xD;
             dosage for at least 28 days prior to the baseline (start of treatment) for RA&#xD;
             treatment:&#xD;
&#xD;
               -  Non-steroidal anti-inflammatory drugs (NSAIDs; excluding topical formulations&#xD;
                  with a local action), oral morphine or equivalent opioid analgesics (≤ 30&#xD;
                  mg/day), acetaminophen, or oral corticosteroids (≤ 10 mg/day in prednisolone&#xD;
                  equivalent)&#xD;
&#xD;
          -  At screening subject has active RA as evidenced by both of the following:&#xD;
&#xD;
               -  ≥ 6 tender/painful joints (using 68-joint assessment)&#xD;
&#xD;
               -  ≥ 6 swollen joints (using 66-joint assessment)&#xD;
&#xD;
          -  CRP (latex agglutination test) of ≥ 1.00 mg/dL at screening.&#xD;
&#xD;
          -  Subject meets the ACR 1991 Revised Criteria for the Classification of Global&#xD;
             Functional Status in RA Class I, II or, III at screening&#xD;
&#xD;
          -  Inadequate responders to MTX which was continuously administered for at least 90 days&#xD;
             prior to screening and MTX ≥ 8 mg/week for at least 28 days prior to baseline.&#xD;
             However, inadequate responder to MTX &lt; 8 mg/week is eligible if intolerance precludes&#xD;
             dose increase and defined as MTX-IR&#xD;
&#xD;
          -  Subject is able to continue stable dose of MTX (a maximum of 16 mg/week) from at least&#xD;
             28 days prior to screening until the end of treatment&#xD;
&#xD;
          -  Subject has bone erosion at the joint (as evidenced by x-rays of hands and feet)&#xD;
             assessed in mTSS and any of the following apply at screening. Bone erosion may be&#xD;
             evidenced by x-rays within 90 days prior to baseline.&#xD;
&#xD;
               -  Positive anti-CCP antibody: ≥ 4.5 U/mL&#xD;
&#xD;
               -  Positive rheumatoid factor: &gt; 15 IU/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has received a biologic DMARD within the specified period&#xD;
&#xD;
          -  Inadequate responders to biologic DMARD as determined by investigator/sub-investigator&#xD;
&#xD;
          -  Subject has received intra-articular, intravenous, intramuscular or endorectal&#xD;
             (excluding suppositories for anal diseases) corticosteroid within 28 days prior to&#xD;
             baseline&#xD;
&#xD;
          -  Subject has participated in any study of ASP015K and has received ASP015K or placebo&#xD;
&#xD;
          -  Subject has received other investigational drugs within 90 days or within 5&#xD;
             half-lives, whichever is longer, prior to baseline&#xD;
&#xD;
          -  Subject has received plasma exchange therapy within 60 days prior to baseline&#xD;
&#xD;
          -  Subject has undergone joint drainage, has received local anesthesia and nerve block,&#xD;
             or has received articular cartilage protectant at the assessed joint within 28 days&#xD;
             prior to baseline&#xD;
&#xD;
          -  Subject has undergone surgery and has residual effects in the assessed joints at the&#xD;
             discretion of investigator/sub-investigator, or is scheduled to undergo surgery that&#xD;
             may affect the study evaluation of the assessed joints at the discretion of&#xD;
             investigator/sub-investigator&#xD;
&#xD;
          -  A diagnosis of inflammatory arthritis (psoriatic arthritis, ankylosing spondylitis,&#xD;
             SLE, sarcoidosis, etc.) other than RA&#xD;
&#xD;
          -  Any of the following laboratory values at screening:&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1000/μL&#xD;
&#xD;
               -  Absolute lymphocyte count &lt; 800/μL&#xD;
&#xD;
               -  Platelet count &lt; 75000/μL&#xD;
&#xD;
               -  ALT ≥ 2 ×ULN&#xD;
&#xD;
               -  AST ≥ 2 × ULN&#xD;
&#xD;
               -  Total bilirubin (TBL) ≥ 1.5 × ULN&#xD;
&#xD;
               -  Estimated GFR ≤ 40 mL/min as measured by the MDRD method&#xD;
&#xD;
               -  β-D-glucan ≥ 11 pg/mL&#xD;
&#xD;
               -  Positive HBs antigen, HBc antibody, HBs antibody or HBV-DNA quantitation&#xD;
                  (However, subject with negative HBs antigen and HBV-DNA quantitation, and&#xD;
                  positive HBc antibody and/or HBs antibody is eligible if HBV-DNA is monitored by&#xD;
                  HBV-DNA quantitation at every scheduled visit after initiation of study drug&#xD;
                  administration.)&#xD;
&#xD;
               -  Positive HCV antibody&#xD;
&#xD;
          -  Subject has a history of or concurrent active tuberculosis (TB)&#xD;
&#xD;
          -  Subject has a history of or concurrent interstitial pneumonia and&#xD;
             investigator/sub-investigator judges that it is inappropriate for the subject to&#xD;
             participate in this study&#xD;
&#xD;
          -  Subject has a history of or concurrent malignant tumor (except for successfully&#xD;
             treated basal cell carcinoma)&#xD;
&#xD;
          -  Subject has received live or live attenuated virus vaccination within 56 days prior to&#xD;
             baseline. (Inactivated vaccines including influenza and pneumococcal vaccines are&#xD;
             allowed.)&#xD;
&#xD;
          -  Subject has any ongoing severe, progressive, or uncontrolled renal, hepatic,&#xD;
             hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac,&#xD;
             neurological, infectious, or autoimmune disease except for RA (excluding Sjogren's&#xD;
             syndrome and chronic thyroiditis), or any ongoing illness which would make the subject&#xD;
             unsuitable for the study as determined by the investigator/sub-investigator&#xD;
&#xD;
          -  Subject has a history of clinically significant allergy. (Clinically significant&#xD;
             allergy includes allergies such as systemic urticaria induced by specific antigens and&#xD;
             drugs, anaphylaxis, and allergy associated with shock necessitating hospitalized&#xD;
             treatment.)&#xD;
&#xD;
          -  Subject has concurrent cardiac failure, defined as NYHA classification Class III or&#xD;
             higher, or a history of it&#xD;
&#xD;
          -  Subject has concurrent prolonged QT syndrome or a history of it. Subject has prolonged&#xD;
             QT interval (defined as QTc ≥ 500 msec. Subject has QTc ≥ 500 msec at retest will be&#xD;
             excluded) at screening&#xD;
&#xD;
          -  Subject has a history of positive HIV infection&#xD;
&#xD;
          -  Subject has congenital short QT syndrome or a history of it. Subject has shortened QT&#xD;
             interval (defined as QTc &lt; 330 msec. Subject has QTc &lt; 330 msec at retest will be&#xD;
             excluded) at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JP00037</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00109</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00130</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00175</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00066</name>
      <address>
        <city>Okazaki</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00108</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00170</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00156</name>
      <address>
        <city>Toyota</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00068</name>
      <address>
        <city>Yatomi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00180</name>
      <address>
        <city>Asahi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00166</name>
      <address>
        <city>Funabashi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00115</name>
      <address>
        <city>Narashino</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00138</name>
      <address>
        <city>Yotsukaido</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00120</name>
      <address>
        <city>Iizuka</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00110</name>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00040</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00119</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00071</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00106</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00033</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00163</name>
      <address>
        <city>Higashihiroshima</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00124</name>
      <address>
        <city>Tomakomai</city>
        <state>Hokaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00026</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00090</name>
      <address>
        <city>Hakodate</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00172</name>
      <address>
        <city>Kitami</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00125</name>
      <address>
        <city>Kushiro</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00001</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00002</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00003</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00038</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00114</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00056</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00069</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00136</name>
      <address>
        <city>Itami</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00113</name>
      <address>
        <city>Kakogawa</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00041</name>
      <address>
        <city>Kato</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00042</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00092</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00154</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00171</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00117</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00181</name>
      <address>
        <city>Hitachinaka</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00107</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00073</name>
      <address>
        <city>Koga</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00054</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00039</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00179</name>
      <address>
        <city>Komatsu</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00049</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00088</name>
      <address>
        <city>Kida</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00084</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00048</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00058</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00141</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00096</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00045</name>
      <address>
        <city>Zushi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00019</name>
      <address>
        <city>Koshi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00057</name>
      <address>
        <city>Tamana</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00168</name>
      <address>
        <city>Yokkaichi</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00169</name>
      <address>
        <city>Osaki</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00004</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00036</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00105</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00151</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00050</name>
      <address>
        <city>Hyuga</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00129</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00162</name>
      <address>
        <city>Isehaya</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00101</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00103</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00153</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00094</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00025</name>
      <address>
        <city>Nagaoka</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00144</name>
      <address>
        <city>Shibata</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00064</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00051</name>
      <address>
        <city>Setouchi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00011</name>
      <address>
        <city>Hannan</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00134</name>
      <address>
        <city>Higashiosaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00178</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00078</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00137</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00070</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00146</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00061</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00075</name>
      <address>
        <city>Ureshino</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00126</name>
      <address>
        <city>Gyoda</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00007</name>
      <address>
        <city>Hiki</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00060</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00161</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00062</name>
      <address>
        <city>Kawaguchi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00052</name>
      <address>
        <city>Sayama</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00008</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00133</name>
      <address>
        <city>Kakegawa</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00077</name>
      <address>
        <city>Kanuma</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00145</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00024</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00143</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00149</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00152</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00099</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00142</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00063</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00053</name>
      <address>
        <city>Kiyose</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00072</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00148</name>
      <address>
        <city>Ota</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00081</name>
      <address>
        <city>Shibuya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00010</name>
      <address>
        <city>Takaoka</city>
        <state>Toyama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00155</name>
      <address>
        <city>Nishimuro</city>
        <state>Wakayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00104</name>
      <address>
        <city>Shimonoseki</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00047</name>
      <address>
        <city>Shunan</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00176</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00018</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00020</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00035</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00059</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00067</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00076</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00131</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00164</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00165</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00013</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00014</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00016</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00055</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00074</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00167</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00093</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00022</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00046</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00085</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00123</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00160</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00023</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00122</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00080</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00174</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00098</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00112</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00147</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00017</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00118</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00150</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00157</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00177</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00044</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00089</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00135</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JP00139</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=336</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <results_first_submitted>June 3, 2020</results_first_submitted>
  <results_first_submitted_qc>July 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2020</results_first_posted>
  <disposition_first_submitted>June 6, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 6, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 11, 2018</disposition_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02305849/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02305849/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) were enrolled in this study.</recruitment_details>
      <pre_assignment_details>Participants were randomized in a 1:1:1 ratio to peficitinib 100 milligram (mg), 150 mg or placebo groups in combination with MTX at baseline. At week 12 or 28, participants in the placebo group were switched to receive either peficitinib at a dose of 100 mg or 150 mg, which was determined in advance randomly.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peficitinib 100 mg</title>
          <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Peficitinib 150 mg</title>
          <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo / Peficitinib 100 mg</title>
          <description>Participants who received placebo matching to peficitinib 100 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
        </group>
        <group group_id="P4">
          <title>Placebo / Peficitinib 150 mg</title>
          <description>Participants who received placebo matching to peficitinib 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="146"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lab data met discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not fulfill eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set (SAF) was defined as all participants who received at least 1 dose of the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Peficitinib 100 mg</title>
          <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Peficitinib 150 mg</title>
          <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="174"/>
            <count group_id="B2" value="174"/>
            <count group_id="B3" value="170"/>
            <count group_id="B4" value="518"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="170"/>
                    <count group_id="B4" value="518"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="10.8"/>
                    <measurement group_id="B2" value="56.2" spread="11.6"/>
                    <measurement group_id="B3" value="55.3" spread="12.1"/>
                    <measurement group_id="B4" value="56.7" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="170"/>
                    <count group_id="B4" value="518"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="364"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="170"/>
                    <count group_id="B4" value="518"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="518"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <description>Higher CRP indicates greater disease activity.</description>
          <population>Full analysis set (FAS) included all participants who were randomized and received at least one dose of the study drug. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>milligram/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.432" spread="2.076"/>
                    <measurement group_id="B2" value="2.524" spread="2.183"/>
                    <measurement group_id="B3" value="2.622" spread="2.146"/>
                    <measurement group_id="B4" value="2.525" spread="2.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erosion Score</title>
          <description>The joint erosion score was a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint in the hand is scored from 0-5 and each joint in the foot is scored from 0-10. The score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet. By summing these score, the range of total erosion score is 0-280. Higher erosion score indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="173"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="516"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.34" spread="17.47"/>
                    <measurement group_id="B2" value="9.76" spread="15.93"/>
                    <measurement group_id="B3" value="11.03" spread="17.96"/>
                    <measurement group_id="B4" value="10.37" spread="17.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR)</title>
          <population>FAS.</population>
          <units>millimeter per hour (mm/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="170"/>
                    <count group_id="B4" value="518"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="26.2"/>
                    <measurement group_id="B2" value="51.5" spread="26.8"/>
                    <measurement group_id="B3" value="53.8" spread="26.9"/>
                    <measurement group_id="B4" value="51.9" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire - Disability Index (HAQ-DI)</title>
          <description>Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.91" spread="0.65"/>
                    <measurement group_id="B2" value="1.02" spread="0.62"/>
                    <measurement group_id="B3" value="1.05" spread="0.66"/>
                    <measurement group_id="B4" value="0.99" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Joint Space Narrowing (JSN) Score</title>
          <description>JSN was defined as narrowing in joint space width over the course of the study. The JSN score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. JSN, including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. Higher joint space narrowing score indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="173"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="516"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.89" spread="19.47"/>
                    <measurement group_id="B2" value="15.23" spread="18.33"/>
                    <measurement group_id="B3" value="17.37" spread="20.13"/>
                    <measurement group_id="B4" value="15.82" spread="19.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Total Sharp Score (mTSS)</title>
          <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints and JSN scores graded by assessing narrowing of joint spaces in 42 joints. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="173"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="516"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.23" spread="35.5"/>
                    <measurement group_id="B2" value="25" spread="32.38"/>
                    <measurement group_id="B3" value="28.4" spread="36.28"/>
                    <measurement group_id="B4" value="26.19" spread="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's Global Assessment of Arthritis (PGA)</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm visual analog scale (VAS) where 0 = very well and 100 = very poorly.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.87" spread="19.67"/>
                    <measurement group_id="B2" value="60.86" spread="19.09"/>
                    <measurement group_id="B3" value="60.98" spread="19.59"/>
                    <measurement group_id="B4" value="60.23" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subject's Global Assessment of Arthritis (SGA)</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="25.25"/>
                    <measurement group_id="B2" value="55.44" spread="24.49"/>
                    <measurement group_id="B3" value="58.18" spread="23.9"/>
                    <measurement group_id="B4" value="55.07" spread="24.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subject's Global Assessment of Arthritis Pain (SGAP)</title>
          <description>The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGAP (100 mm VAS) scores indicated greater activity pain.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.12" spread="26.14"/>
                    <measurement group_id="B2" value="55.09" spread="24.89"/>
                    <measurement group_id="B3" value="56.75" spread="25.29"/>
                    <measurement group_id="B4" value="54.3" spread="25.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count (SJC) (66 Joints)</title>
          <description>The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the 66 joints. Higher SJC indicated greater disease activity.</description>
          <population>FAS.</population>
          <units>swollen joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="170"/>
                    <count group_id="B4" value="518"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="6.8"/>
                    <measurement group_id="B2" value="13.1" spread="6.9"/>
                    <measurement group_id="B3" value="13.6" spread="7"/>
                    <measurement group_id="B4" value="13.2" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count (TJC) (68 Joints)</title>
          <description>The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the 68 joints. Higher TJC indicated greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>tender joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="174"/>
                    <count group_id="B3" value="169"/>
                    <count group_id="B4" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" spread="8.6"/>
                    <measurement group_id="B2" value="14.5" spread="7.8"/>
                    <measurement group_id="B3" value="15.4" spread="9.4"/>
                    <measurement group_id="B4" value="14.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12</title>
        <description>ACR20 response: greater than and equal to (≥) 20 percent (%) improvement in tender and swollen joint count; and ≥ 20% improvement in at least 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.</description>
        <time_frame>Baseline and week 12/Early termination (ET)</time_frame>
        <population>FAS. Last observation carried forward (LOCF) was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12</title>
          <description>ACR20 response: greater than and equal to (≥) 20 percent (%) improvement in tender and swollen joint count; and ≥ 20% improvement in at least 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.</description>
          <population>FAS. Last observation carried forward (LOCF) was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="58.6"/>
                    <measurement group_id="O3" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Closed testing procedure was used for multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>36.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.7</ci_lower_limit>
            <ci_upper_limit>47.0</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Closed testing procedure was used for multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent difference</param_type>
            <param_value>42.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.6</ci_lower_limit>
            <ci_upper_limit>52.6</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in mTSS at Week 28</title>
        <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change from baseline was calculated as score at week 28 (ET) minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
        <time_frame>Baseline and week 28/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in mTSS at Week 28</title>
          <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change from baseline was calculated as score at week 28 (ET) minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="5.46"/>
                    <measurement group_id="O2" value="1.62" spread="4.23"/>
                    <measurement group_id="O3" value="1.03" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Closed testing procedure was used for multiplicity adjustment.</p_value_desc>
            <method>RANCOVA</method>
            <method_desc>Based on Rank Analysis of Covariance (RANCOVA) Model: Rank of mTSS Change = Treatment + Baseline Rank of mTSS.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Closed testing procedure was used for multiplicity adjustment.</p_value_desc>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of mTSS Change = Treatment + Baseline Rank of mTSS.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an ACR20-CRP Response Through Week 52</title>
        <description>ACR20 response:≥ 20% improvement in tender and swollen joint count; and ≥ 20% improvement in at least 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. EOT was defined as end of treatment i.e, either early termination or week 52.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 100 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Peficitinib 150 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an ACR20-CRP Response Through Week 52</title>
          <description>ACR20 response:≥ 20% improvement in tender and swollen joint count; and ≥ 20% improvement in at least 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. EOT was defined as end of treatment i.e, either early termination or week 52.</description>
          <population>FAS. Here, number of participants analyzed signifies participants with available data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="48.2"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="2.7"/>
                    <measurement group_id="O5" value="38.5"/>
                    <measurement group_id="O6" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="62.0"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5"/>
                    <measurement group_id="O2" value="66.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="51.3"/>
                    <measurement group_id="O6" value="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="77.0"/>
                    <measurement group_id="O3" value="43.2"/>
                    <measurement group_id="O4" value="51.4"/>
                    <measurement group_id="O5" value="64.1"/>
                    <measurement group_id="O6" value="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4"/>
                    <measurement group_id="O2" value="79.8"/>
                    <measurement group_id="O3" value="59.5"/>
                    <measurement group_id="O4" value="67.6"/>
                    <measurement group_id="O5" value="61.5"/>
                    <measurement group_id="O6" value="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5"/>
                    <measurement group_id="O2" value="85.0"/>
                    <measurement group_id="O3" value="63.9"/>
                    <measurement group_id="O4" value="80.6"/>
                    <measurement group_id="O5" value="59.0"/>
                    <measurement group_id="O6" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                    <measurement group_id="O2" value="83.0"/>
                    <measurement group_id="O3" value="72.2"/>
                    <measurement group_id="O4" value="83.3"/>
                    <measurement group_id="O5" value="64.1"/>
                    <measurement group_id="O6" value="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6"/>
                    <measurement group_id="O2" value="85.2"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="86.1"/>
                    <measurement group_id="O5" value="84.6"/>
                    <measurement group_id="O6" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4"/>
                    <measurement group_id="O2" value="86.5"/>
                    <measurement group_id="O3" value="80.6"/>
                    <measurement group_id="O4" value="85.7"/>
                    <measurement group_id="O5" value="78.4"/>
                    <measurement group_id="O6" value="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="80.0"/>
                    <measurement group_id="O4" value="88.2"/>
                    <measurement group_id="O5" value="88.9"/>
                    <measurement group_id="O6" value="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="76.5"/>
                    <measurement group_id="O4" value="90.9"/>
                    <measurement group_id="O5" value="88.9"/>
                    <measurement group_id="O6" value="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8"/>
                    <measurement group_id="O2" value="89.4"/>
                    <measurement group_id="O3" value="81.8"/>
                    <measurement group_id="O4" value="90.9"/>
                    <measurement group_id="O5" value="85.7"/>
                    <measurement group_id="O6" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8"/>
                    <measurement group_id="O2" value="87.1"/>
                    <measurement group_id="O3" value="75.8"/>
                    <measurement group_id="O4" value="90.9"/>
                    <measurement group_id="O5" value="91.2"/>
                    <measurement group_id="O6" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4"/>
                    <measurement group_id="O2" value="81.0"/>
                    <measurement group_id="O3" value="73.0"/>
                    <measurement group_id="O4" value="78.9"/>
                    <measurement group_id="O5" value="92.3"/>
                    <measurement group_id="O6" value="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an ACR50-CRP Response at Week 12</title>
        <description>ACR50 response: ≥50% improvement in tender and swollen joint counts and 50% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an ACR50-CRP Response at Week 12</title>
          <description>ACR50 response: ≥50% improvement in tender and swollen joint counts and 50% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
          <population>FAS. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="29.9"/>
                    <measurement group_id="O3" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>22.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.8</ci_lower_limit>
            <ci_upper_limit>30.7</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>38.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.3</ci_lower_limit>
            <ci_upper_limit>47.3</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an ACR50-CRP Response Through Week 52</title>
        <description>ACR50 response: ≥50% improvement in tender and swollen joint counts and 50% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 100 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Peficitinib 150 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an ACR50-CRP Response Through Week 52</title>
          <description>ACR50 response: ≥50% improvement in tender and swollen joint counts and 50% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="15.9"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="33.1"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="12.8"/>
                    <measurement group_id="O6" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                    <measurement group_id="O2" value="48.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="23.1"/>
                    <measurement group_id="O6" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4"/>
                    <measurement group_id="O2" value="53.9"/>
                    <measurement group_id="O3" value="13.5"/>
                    <measurement group_id="O4" value="21.6"/>
                    <measurement group_id="O5" value="38.5"/>
                    <measurement group_id="O6" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="54.6"/>
                    <measurement group_id="O3" value="35.1"/>
                    <measurement group_id="O4" value="37.8"/>
                    <measurement group_id="O5" value="35.9"/>
                    <measurement group_id="O6" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5"/>
                    <measurement group_id="O2" value="60.6"/>
                    <measurement group_id="O3" value="47.2"/>
                    <measurement group_id="O4" value="52.8"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="63.5"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="69.4"/>
                    <measurement group_id="O5" value="28.2"/>
                    <measurement group_id="O6" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="65.8"/>
                    <measurement group_id="O3" value="52.8"/>
                    <measurement group_id="O4" value="61.1"/>
                    <measurement group_id="O5" value="56.4"/>
                    <measurement group_id="O6" value="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="67.7"/>
                    <measurement group_id="O3" value="58.3"/>
                    <measurement group_id="O4" value="71.4"/>
                    <measurement group_id="O5" value="64.9"/>
                    <measurement group_id="O6" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8"/>
                    <measurement group_id="O2" value="68.0"/>
                    <measurement group_id="O3" value="48.6"/>
                    <measurement group_id="O4" value="67.6"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                    <measurement group_id="O2" value="71.2"/>
                    <measurement group_id="O3" value="52.9"/>
                    <measurement group_id="O4" value="72.7"/>
                    <measurement group_id="O5" value="72.2"/>
                    <measurement group_id="O6" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                    <measurement group_id="O2" value="64.9"/>
                    <measurement group_id="O3" value="60.6"/>
                    <measurement group_id="O4" value="69.7"/>
                    <measurement group_id="O5" value="71.4"/>
                    <measurement group_id="O6" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                    <measurement group_id="O2" value="68.0"/>
                    <measurement group_id="O3" value="63.6"/>
                    <measurement group_id="O4" value="63.6"/>
                    <measurement group_id="O5" value="67.6"/>
                    <measurement group_id="O6" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3"/>
                    <measurement group_id="O2" value="62.6"/>
                    <measurement group_id="O3" value="62.2"/>
                    <measurement group_id="O4" value="55.3"/>
                    <measurement group_id="O5" value="69.2"/>
                    <measurement group_id="O6" value="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an ACR70-CRP Response at Week 12</title>
        <description>ACR70 response: ≥ 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an ACR70-CRP Response at Week 12</title>
          <description>ACR70 response: ≥ 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
          <population>FAS. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="12.1"/>
                    <measurement group_id="O3" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>9.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.8</ci_lower_limit>
            <ci_upper_limit>15.6</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>21.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.9</ci_lower_limit>
            <ci_upper_limit>28.5</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an ACR70-CRP Response Through Week 52</title>
        <description>ACR70 response: ≥ 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 100 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Peficitinib 150 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an ACR70-CRP Response Through Week 52</title>
          <description>ACR70 response: ≥ 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the following 5 criteria compared with baseline: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional ability via a health assessment questionnaire-Disability Index, and 5) C-reactive protein at each visit.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="2.6"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="13.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="2.6"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="7.7"/>
                    <measurement group_id="O6" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="32.1"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="2.7"/>
                    <measurement group_id="O5" value="12.8"/>
                    <measurement group_id="O6" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="35.0"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="2.7"/>
                    <measurement group_id="O5" value="12.8"/>
                    <measurement group_id="O6" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="161"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7"/>
                    <measurement group_id="O2" value="36.0"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="17.9"/>
                    <measurement group_id="O6" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="42.8"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="38.9"/>
                    <measurement group_id="O5" value="17.9"/>
                    <measurement group_id="O6" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="43.9"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="44.4"/>
                    <measurement group_id="O5" value="20.5"/>
                    <measurement group_id="O6" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="42.9"/>
                    <measurement group_id="O5" value="13.5"/>
                    <measurement group_id="O6" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="41.8"/>
                    <measurement group_id="O3" value="31.4"/>
                    <measurement group_id="O4" value="38.2"/>
                    <measurement group_id="O5" value="36.1"/>
                    <measurement group_id="O6" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="48.4"/>
                    <measurement group_id="O3" value="41.2"/>
                    <measurement group_id="O4" value="36.4"/>
                    <measurement group_id="O5" value="38.9"/>
                    <measurement group_id="O6" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="49.0"/>
                    <measurement group_id="O3" value="45.5"/>
                    <measurement group_id="O4" value="42.4"/>
                    <measurement group_id="O5" value="45.7"/>
                    <measurement group_id="O6" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="52.4"/>
                    <measurement group_id="O3" value="42.4"/>
                    <measurement group_id="O4" value="48.5"/>
                    <measurement group_id="O5" value="44.1"/>
                    <measurement group_id="O6" value="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="48.3"/>
                    <measurement group_id="O3" value="40.5"/>
                    <measurement group_id="O4" value="42.1"/>
                    <measurement group_id="O5" value="43.6"/>
                    <measurement group_id="O6" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in mTSS at Week 52</title>
        <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change from baseline was calculated as score at week 52 (ET) minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
        <time_frame>Baseline and week 52/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in mTSS at Week 52</title>
          <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change from baseline was calculated as score at week 52 (ET) minus score at baseline. An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" spread="10.18"/>
                    <measurement group_id="O2" value="2.12" spread="5.83"/>
                    <measurement group_id="O3" value="1.54" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on RANCOVA Model: Rank of mTSS Change = Treatment + Baseline Rank of mTSS.</p_value_desc>
            <method>RANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on RANCOVA Model: Rank of mTSS Change = Treatment + Baseline Rank of mTSS.</p_value_desc>
            <method>RANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in JSN Score at Week 28 and Week 52</title>
        <description>JSN was defined as narrowing in joint space width over the course of the study. The JSN score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. JSN, including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. Higher scores indicate greater disease activity.</description>
        <time_frame>Baseline and weeks 28/ET and 52/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in JSN Score at Week 28 and Week 52</title>
          <description>JSN was defined as narrowing in joint space width over the course of the study. The JSN score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. JSN, including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. Higher scores indicate greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 28/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="3.76"/>
                    <measurement group_id="O2" value="0.99" spread="2.86"/>
                    <measurement group_id="O3" value="0.82" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="7.01"/>
                    <measurement group_id="O2" value="1.30" spread="3.37"/>
                    <measurement group_id="O3" value="1.19" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of JSN Score Change = Treatment + Baseline Rank of JSN score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 28/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of JSN Score Change = Treatment + Baseline Rank of JSN score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of JSN Score Change = Treatment + Baseline Rank of JSN Score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of JSN Score Change = Treatment + Baseline Rank of JSN Score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erosion Score at Week 28 and Week 52</title>
        <description>The joint erosion score was a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint in the hand is scored from 0-5 and each joint in the foot is scored from 0-10. The score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet. By summing these score, the range of total erosion score is 0-280. Higher erosion score indicates greater disease activity.</description>
        <time_frame>Baseline and weeks 28/ET and 52/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erosion Score at Week 28 and Week 52</title>
          <description>The joint erosion score was a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint in the hand is scored from 0-5 and each joint in the foot is scored from 0-10. The score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet. By summing these score, the range of total erosion score is 0-280. Higher erosion score indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 28/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="3.01"/>
                    <measurement group_id="O2" value="0.63" spread="2.03"/>
                    <measurement group_id="O3" value="0.18" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="5.58"/>
                    <measurement group_id="O2" value="0.82" spread="3.14"/>
                    <measurement group_id="O3" value="0.32" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of Erosion Score Change = Treatment + Baseline Rank of Erosion Score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 28/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of Erosion Score Change = Treatment + Baseline Rank of Erosion Score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of Erosion Score Change = Treatment + Baseline Rank of Erosion Score.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>RANCOVA</method>
            <method_desc>Based on RANCOVA Model: Rank of Erosion Score Change = Treatment + Baseline Rank of Erosion Score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Change From Baseline in mTSS &lt;= 0.5 at Week 28 and Week 52</title>
        <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
        <time_frame>Baseline and week 28/ET and 52/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Change From Baseline in mTSS &lt;= 0.5 at Week 28 and Week 52</title>
          <description>mTSS was defined as the sum of joint erosion scores graded by assessing erosion severity in 44 joints (16 per hand and 6 per feet) and JSN scores graded by assessing narrowing of joint spaces in 42 joints (15 per hand and 6 per feet). Erosion score was scored from 0 (no erosion) to 5 (complete collapse of bone) and the score for erosion ranges from 0 to 160 in the hands and from 0 to 120 in the feet (the maximum erosion score for a joint in the foot is 10). JSN including subluxation, was scored from 0 (normal) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. mTSS scores ranged from 0 (normal) to 448 (worst possible total score). An increase in mTSS from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Missing values were imputed by linear extrapolation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 28/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8"/>
                    <measurement group_id="O2" value="67.1"/>
                    <measurement group_id="O3" value="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                    <measurement group_id="O2" value="64.0"/>
                    <measurement group_id="O3" value="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 28/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>21.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.0</ci_lower_limit>
            <ci_upper_limit>32.6</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 28/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>26.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.7</ci_lower_limit>
            <ci_upper_limit>37.9</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>21.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.2</ci_lower_limit>
            <ci_upper_limit>32.9</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 52/ET: Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>26.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.2</ci_lower_limit>
            <ci_upper_limit>37.6</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score (DAS) 28-CRP at Week 12</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score (DAS) 28-CRP at Week 12</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="1.10"/>
                    <measurement group_id="O2" value="-1.70" spread="1.20"/>
                    <measurement group_id="O3" value="-2.09" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA (analysis of covariance) Model: DAS28 Change = Treatment + Baseline DAS28.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>-0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: DAS28 Change = Treatment + Baseline DAS28.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>-1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-CRP Through Week 52</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 100 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Peficitinib 150 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP Through Week 52</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
          <population>FAS. Here, number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="0.81"/>
                    <measurement group_id="O2" value="-1.39" spread="0.98"/>
                    <measurement group_id="O3" value="-0.28" spread="0.67"/>
                    <measurement group_id="O4" value="-0.30" spread="0.56"/>
                    <measurement group_id="O5" value="-0.82" spread="1.09"/>
                    <measurement group_id="O6" value="-0.74" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="1.00"/>
                    <measurement group_id="O2" value="-1.87" spread="1.16"/>
                    <measurement group_id="O3" value="-0.21" spread="0.86"/>
                    <measurement group_id="O4" value="-0.10" spread="0.63"/>
                    <measurement group_id="O5" value="-0.94" spread="0.97"/>
                    <measurement group_id="O6" value="-0.90" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="1.19"/>
                    <measurement group_id="O2" value="-2.15" spread="1.29"/>
                    <measurement group_id="O3" value="0.24" spread="0.75"/>
                    <measurement group_id="O4" value="0.27" spread="0.60"/>
                    <measurement group_id="O5" value="-1.34" spread="1.00"/>
                    <measurement group_id="O6" value="-1.20" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.18"/>
                    <measurement group_id="O2" value="-2.40" spread="1.30"/>
                    <measurement group_id="O3" value="-1.11" spread="1.15"/>
                    <measurement group_id="O4" value="-1.37" spread="1.18"/>
                    <measurement group_id="O5" value="-1.37" spread="1.35"/>
                    <measurement group_id="O6" value="-1.31" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="1.24"/>
                    <measurement group_id="O2" value="-2.53" spread="1.29"/>
                    <measurement group_id="O3" value="-1.69" spread="1.22"/>
                    <measurement group_id="O4" value="-1.76" spread="1.24"/>
                    <measurement group_id="O5" value="-1.38" spread="1.19"/>
                    <measurement group_id="O6" value="-1.48" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.40" spread="1.21"/>
                    <measurement group_id="O2" value="-2.71" spread="1.18"/>
                    <measurement group_id="O3" value="-2.01" spread="1.26"/>
                    <measurement group_id="O4" value="-2.26" spread="1.07"/>
                    <measurement group_id="O5" value="-1.41" spread="1.32"/>
                    <measurement group_id="O6" value="-1.64" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="1.21"/>
                    <measurement group_id="O2" value="-2.70" spread="1.25"/>
                    <measurement group_id="O3" value="-2.24" spread="1.11"/>
                    <measurement group_id="O4" value="-2.51" spread="1.13"/>
                    <measurement group_id="O5" value="-1.53" spread="1.39"/>
                    <measurement group_id="O6" value="-1.71" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="1.18"/>
                    <measurement group_id="O2" value="-2.77" spread="1.19"/>
                    <measurement group_id="O3" value="-2.49" spread="1.24"/>
                    <measurement group_id="O4" value="-2.72" spread="1.27"/>
                    <measurement group_id="O5" value="-2.18" spread="1.27"/>
                    <measurement group_id="O6" value="-2.47" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="1.12"/>
                    <measurement group_id="O2" value="-2.83" spread="1.20"/>
                    <measurement group_id="O3" value="-2.49" spread="1.14"/>
                    <measurement group_id="O4" value="-2.70" spread="1.22"/>
                    <measurement group_id="O5" value="-2.22" spread="1.23"/>
                    <measurement group_id="O6" value="-2.57" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.66" spread="1.16"/>
                    <measurement group_id="O2" value="-2.86" spread="1.14"/>
                    <measurement group_id="O3" value="-2.66" spread="1.24"/>
                    <measurement group_id="O4" value="-2.72" spread="1.13"/>
                    <measurement group_id="O5" value="-2.62" spread="1.05"/>
                    <measurement group_id="O6" value="-2.73" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="1.13"/>
                    <measurement group_id="O2" value="-2.88" spread="1.15"/>
                    <measurement group_id="O3" value="-2.68" spread="1.23"/>
                    <measurement group_id="O4" value="-2.72" spread="1.19"/>
                    <measurement group_id="O5" value="-2.63" spread="1.35"/>
                    <measurement group_id="O6" value="-2.87" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.62" spread="1.15"/>
                    <measurement group_id="O2" value="-2.92" spread="1.14"/>
                    <measurement group_id="O3" value="-2.86" spread="1.26"/>
                    <measurement group_id="O4" value="-2.90" spread="1.18"/>
                    <measurement group_id="O5" value="-2.66" spread="1.49"/>
                    <measurement group_id="O6" value="-2.96" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.67" spread="1.19"/>
                    <measurement group_id="O2" value="-2.96" spread="1.24"/>
                    <measurement group_id="O3" value="-2.80" spread="1.46"/>
                    <measurement group_id="O4" value="-2.74" spread="1.13"/>
                    <measurement group_id="O5" value="-2.70" spread="1.32"/>
                    <measurement group_id="O6" value="-2.89" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" spread="1.37"/>
                    <measurement group_id="O2" value="-2.76" spread="1.40"/>
                    <measurement group_id="O3" value="-2.61" spread="1.62"/>
                    <measurement group_id="O4" value="-2.52" spread="1.25"/>
                    <measurement group_id="O5" value="-2.72" spread="1.26"/>
                    <measurement group_id="O6" value="-2.87" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-ESR at Week 12</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-ESR at Week 12</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="1.11"/>
                    <measurement group_id="O2" value="-1.66" spread="1.22"/>
                    <measurement group_id="O3" value="-2.12" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: DAS28 Change = Treatment + Baseline DAS28.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>-0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: DAS28 Change = Treatment + Baseline DAS28.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>-1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-ESR Score Through Week 52</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 100 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Peficitinib 150 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-ESR Score Through Week 52</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.83"/>
                    <measurement group_id="O2" value="-1.37" spread="1.02"/>
                    <measurement group_id="O3" value="-0.26" spread="0.66"/>
                    <measurement group_id="O4" value="-0.26" spread="0.59"/>
                    <measurement group_id="O5" value="-0.87" spread="1.08"/>
                    <measurement group_id="O6" value="-0.67" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.06"/>
                    <measurement group_id="O2" value="-1.88" spread="1.18"/>
                    <measurement group_id="O3" value="-0.24" spread="0.88"/>
                    <measurement group_id="O4" value="-0.12" spread="0.64"/>
                    <measurement group_id="O5" value="-1.00" spread="0.93"/>
                    <measurement group_id="O6" value="-0.85" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="1.21"/>
                    <measurement group_id="O2" value="-2.18" spread="1.32"/>
                    <measurement group_id="O3" value="0.24" spread="0.76"/>
                    <measurement group_id="O4" value="0.25" spread="0.59"/>
                    <measurement group_id="O5" value="-1.40" spread="0.99"/>
                    <measurement group_id="O6" value="-1.10" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.98" spread="1.22"/>
                    <measurement group_id="O2" value="-2.46" spread="1.32"/>
                    <measurement group_id="O3" value="-1.01" spread="1.14"/>
                    <measurement group_id="O4" value="-1.38" spread="1.21"/>
                    <measurement group_id="O5" value="-1.47" spread="1.39"/>
                    <measurement group_id="O6" value="-1.21" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.27"/>
                    <measurement group_id="O2" value="-2.60" spread="1.35"/>
                    <measurement group_id="O3" value="-1.61" spread="1.23"/>
                    <measurement group_id="O4" value="-1.78" spread="1.26"/>
                    <measurement group_id="O5" value="-1.45" spread="1.19"/>
                    <measurement group_id="O6" value="-1.37" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" spread="1.28"/>
                    <measurement group_id="O2" value="-2.78" spread="1.25"/>
                    <measurement group_id="O3" value="-1.94" spread="1.24"/>
                    <measurement group_id="O4" value="-2.24" spread="1.16"/>
                    <measurement group_id="O5" value="-1.47" spread="1.31"/>
                    <measurement group_id="O6" value="-1.56" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="158"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="1.31"/>
                    <measurement group_id="O2" value="-2.79" spread="1.29"/>
                    <measurement group_id="O3" value="-2.11" spread="1.16"/>
                    <measurement group_id="O4" value="-2.48" spread="1.15"/>
                    <measurement group_id="O5" value="-1.63" spread="1.41"/>
                    <measurement group_id="O6" value="-1.62" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="1.31"/>
                    <measurement group_id="O2" value="-2.87" spread="1.27"/>
                    <measurement group_id="O3" value="-2.39" spread="1.26"/>
                    <measurement group_id="O4" value="-2.68" spread="1.30"/>
                    <measurement group_id="O5" value="-2.27" spread="1.34"/>
                    <measurement group_id="O6" value="-2.37" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.59" spread="1.23"/>
                    <measurement group_id="O2" value="-2.91" spread="1.25"/>
                    <measurement group_id="O3" value="-2.45" spread="1.20"/>
                    <measurement group_id="O4" value="-2.71" spread="1.20"/>
                    <measurement group_id="O5" value="-2.38" spread="1.29"/>
                    <measurement group_id="O6" value="-2.54" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" spread="1.22"/>
                    <measurement group_id="O2" value="-2.96" spread="1.20"/>
                    <measurement group_id="O3" value="-2.60" spread="1.34"/>
                    <measurement group_id="O4" value="-2.78" spread="1.11"/>
                    <measurement group_id="O5" value="-2.71" spread="1.16"/>
                    <measurement group_id="O6" value="-2.68" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="1.19"/>
                    <measurement group_id="O2" value="-3.00" spread="1.25"/>
                    <measurement group_id="O3" value="-2.63" spread="1.25"/>
                    <measurement group_id="O4" value="-2.76" spread="1.25"/>
                    <measurement group_id="O5" value="-2.74" spread="1.43"/>
                    <measurement group_id="O6" value="-2.78" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="1.20"/>
                    <measurement group_id="O2" value="-3.01" spread="1.22"/>
                    <measurement group_id="O3" value="-2.80" spread="1.36"/>
                    <measurement group_id="O4" value="-2.88" spread="1.23"/>
                    <measurement group_id="O5" value="-2.72" spread="1.58"/>
                    <measurement group_id="O6" value="-2.93" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" spread="1.27"/>
                    <measurement group_id="O2" value="-3.07" spread="1.28"/>
                    <measurement group_id="O3" value="-2.77" spread="1.54"/>
                    <measurement group_id="O4" value="-2.78" spread="1.24"/>
                    <measurement group_id="O5" value="-2.79" spread="1.33"/>
                    <measurement group_id="O6" value="-2.85" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="1.43"/>
                    <measurement group_id="O2" value="-2.86" spread="1.44"/>
                    <measurement group_id="O3" value="-2.60" spread="1.69"/>
                    <measurement group_id="O4" value="-2.56" spread="1.34"/>
                    <measurement group_id="O5" value="-2.80" spread="1.27"/>
                    <measurement group_id="O6" value="-2.82" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC (68 Joints) at Week 12</title>
        <description>The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the following 68 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher TJC indicated greater disease activity.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC (68 Joints) at Week 12</title>
          <description>The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the following 68 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher TJC indicated greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>tender joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="8.2"/>
                    <measurement group_id="O2" value="-6.9" spread="8.6"/>
                    <measurement group_id="O3" value="-9.1" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: TJC68 Change = Treatment + Baseline TJC68.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-5.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>-3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: TJC68 Change = Treatment + Baseline TJC68.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-7.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>-5.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TJC (68 Joints) Through Week 52</title>
        <description>The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the following 68 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher TJC indicated greater disease activity.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TJC (68 Joints) Through Week 52</title>
          <description>The participants were examined for the tender joints and the location was confirmed by the investigator who assessed the following 68 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher TJC indicated greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>tender joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="5.8"/>
                    <measurement group_id="O2" value="-6.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="7.2"/>
                    <measurement group_id="O2" value="-8.3" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="8.6"/>
                    <measurement group_id="O2" value="-9.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="7.8"/>
                    <measurement group_id="O2" value="-10.5" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="7.9"/>
                    <measurement group_id="O2" value="-10.8" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="7.5"/>
                    <measurement group_id="O2" value="-11.3" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="7.4"/>
                    <measurement group_id="O2" value="-11.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="7.2"/>
                    <measurement group_id="O2" value="-12.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="7.6"/>
                    <measurement group_id="O2" value="-11.8" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="7.2"/>
                    <measurement group_id="O2" value="-11.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="7.4"/>
                    <measurement group_id="O2" value="-12.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="7.1"/>
                    <measurement group_id="O2" value="-12.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="7.4"/>
                    <measurement group_id="O2" value="-11.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="7.8"/>
                    <measurement group_id="O2" value="-11.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC (66 Joints) at Week 12</title>
        <description>The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the following 66 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher SJC indicated greater disease activity.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC (66 Joints) at Week 12</title>
          <description>The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the following 66 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher SJC indicated greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>swollen joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="6.6"/>
                    <measurement group_id="O2" value="-5.9" spread="6.7"/>
                    <measurement group_id="O3" value="-7.6" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SJC66 Change = Treatment + Baseline SJC66.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SJC66 Change = Treatment + Baseline SJC66.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-5.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SJC (66 Joints) Through Week 52</title>
        <description>The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the following 66 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher SJC indicated greater disease activity.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SJC (66 Joints) Through Week 52</title>
          <description>The participants were examined for the swollen joints and the location was confirmed by the investigator who assessed the following 66 joints which included temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8). Higher SJC indicated greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>swollen joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.5"/>
                    <measurement group_id="O2" value="-5.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="5.5"/>
                    <measurement group_id="O2" value="-7.1" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="6.7"/>
                    <measurement group_id="O2" value="-7.8" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="6.2"/>
                    <measurement group_id="O2" value="-8.9" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="6.1"/>
                    <measurement group_id="O2" value="-9.2" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="6.4"/>
                    <measurement group_id="O2" value="-9.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="6.2"/>
                    <measurement group_id="O2" value="-9.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="6.2"/>
                    <measurement group_id="O2" value="-10.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="6.1"/>
                    <measurement group_id="O2" value="-10.5" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="6.1"/>
                    <measurement group_id="O2" value="-10.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="6.1"/>
                    <measurement group_id="O2" value="-10.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="6.2"/>
                    <measurement group_id="O2" value="-11.0" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="6.2"/>
                    <measurement group_id="O2" value="-11.0" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="6.6"/>
                    <measurement group_id="O2" value="-10.3" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-CRP Score &lt; 2.6 at Week 12</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-CRP Score &lt; 2.6 at Week 12</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="31.4"/>
                    <measurement group_id="O3" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>23.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.1</ci_lower_limit>
            <ci_upper_limit>32.3</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>27.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.6</ci_lower_limit>
            <ci_upper_limit>36.2</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-CRP Score &lt; 2.6 Through Week 52</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 100 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Peficitinib 150 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-CRP Score &lt; 2.6 Through Week 52</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="36.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="20.5"/>
                    <measurement group_id="O6" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="43.0"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="13.5"/>
                    <measurement group_id="O5" value="20.5"/>
                    <measurement group_id="O6" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7"/>
                    <measurement group_id="O2" value="52.1"/>
                    <measurement group_id="O3" value="21.6"/>
                    <measurement group_id="O4" value="16.2"/>
                    <measurement group_id="O5" value="17.9"/>
                    <measurement group_id="O6" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6"/>
                    <measurement group_id="O2" value="56.9"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="20.5"/>
                    <measurement group_id="O6" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="52.8"/>
                    <measurement group_id="O3" value="30.6"/>
                    <measurement group_id="O4" value="38.9"/>
                    <measurement group_id="O5" value="25.6"/>
                    <measurement group_id="O6" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1"/>
                    <measurement group_id="O2" value="52.9"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="30.8"/>
                    <measurement group_id="O6" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="53.5"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="48.6"/>
                    <measurement group_id="O5" value="35.1"/>
                    <measurement group_id="O6" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="61.1"/>
                    <measurement group_id="O6" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0"/>
                    <measurement group_id="O2" value="55.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="42.4"/>
                    <measurement group_id="O5" value="55.6"/>
                    <measurement group_id="O6" value="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                    <measurement group_id="O2" value="60.3"/>
                    <measurement group_id="O3" value="54.5"/>
                    <measurement group_id="O4" value="54.5"/>
                    <measurement group_id="O5" value="62.9"/>
                    <measurement group_id="O6" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="62.6"/>
                    <measurement group_id="O3" value="54.5"/>
                    <measurement group_id="O4" value="39.4"/>
                    <measurement group_id="O5" value="55.9"/>
                    <measurement group_id="O6" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4"/>
                    <measurement group_id="O2" value="57.9"/>
                    <measurement group_id="O3" value="54.1"/>
                    <measurement group_id="O4" value="34.2"/>
                    <measurement group_id="O5" value="56.4"/>
                    <measurement group_id="O6" value="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-ESR Score &lt; 2.6 at Week 12</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-ESR Score &lt; 2.6 at Week 12</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="12.8"/>
                    <measurement group_id="O3" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.3</ci_lower_limit>
            <ci_upper_limit>16.5</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>16.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.0</ci_lower_limit>
            <ci_upper_limit>23.9</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-ESR Score &lt; 2.6 Through Week 52</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 100 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Peficitinib 150 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-ESR Score &lt; 2.6 Through Week 52</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="2.6"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="2.6"/>
                    <measurement group_id="O6" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="19.9"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="5.1"/>
                    <measurement group_id="O6" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1"/>
                    <measurement group_id="O2" value="24.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="10.8"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6"/>
                    <measurement group_id="O2" value="33.1"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="10.8"/>
                    <measurement group_id="O5" value="7.7"/>
                    <measurement group_id="O6" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="27.8"/>
                    <measurement group_id="O5" value="12.8"/>
                    <measurement group_id="O6" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="32.1"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="22.2"/>
                    <measurement group_id="O5" value="12.8"/>
                    <measurement group_id="O6" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="41.3"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="30.6"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="13.9"/>
                    <measurement group_id="O4" value="37.1"/>
                    <measurement group_id="O5" value="13.5"/>
                    <measurement group_id="O6" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1"/>
                    <measurement group_id="O2" value="36.2"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="35.3"/>
                    <measurement group_id="O5" value="22.2"/>
                    <measurement group_id="O6" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="37.3"/>
                    <measurement group_id="O3" value="17.6"/>
                    <measurement group_id="O4" value="24.2"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="151"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="40.4"/>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="39.4"/>
                    <measurement group_id="O5" value="34.3"/>
                    <measurement group_id="O6" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="27.3"/>
                    <measurement group_id="O4" value="36.4"/>
                    <measurement group_id="O5" value="26.5"/>
                    <measurement group_id="O6" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="38.6"/>
                    <measurement group_id="O3" value="24.3"/>
                    <measurement group_id="O4" value="31.6"/>
                    <measurement group_id="O5" value="25.6"/>
                    <measurement group_id="O6" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-CRP Score &lt;= 3.2 at Week 12</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-CRP Score &lt;= 3.2 at Week 12</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>34.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.1</ci_lower_limit>
            <ci_upper_limit>44.2</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>45.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.0</ci_lower_limit>
            <ci_upper_limit>55.0</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-CRP Score &lt;= 3.2 Through Week 52</title>
        <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-CRP Score &lt;= 3.2 Through Week 52</title>
          <description>DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0"/>
                    <measurement group_id="O2" value="59.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                    <measurement group_id="O2" value="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7"/>
                    <measurement group_id="O2" value="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6"/>
                    <measurement group_id="O2" value="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3"/>
                    <measurement group_id="O2" value="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3"/>
                    <measurement group_id="O2" value="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6"/>
                    <measurement group_id="O2" value="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7"/>
                    <measurement group_id="O2" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                    <measurement group_id="O2" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-ESR Score &lt;= 3.2 at Week 12</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-ESR Score &lt;= 3.2 at Week 12</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>20.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.5</ci_lower_limit>
            <ci_upper_limit>28.1</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>31.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.1</ci_lower_limit>
            <ci_upper_limit>40.0</ci_upper_limit>
            <estimate_desc>C.I. was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28-ESR Score &lt;= 3.2 Through Week 52</title>
        <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28-ESR Score &lt;= 3.2 Through Week 52</title>
          <description>DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to description: DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                    <measurement group_id="O2" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8"/>
                    <measurement group_id="O2" value="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6"/>
                    <measurement group_id="O2" value="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CRP at Week 12</title>
        <description>Higher CRP indicates greater disease activity.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CRP at Week 12</title>
          <description>Higher CRP indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="2.038"/>
                    <measurement group_id="O2" value="-1.499" spread="1.855"/>
                    <measurement group_id="O3" value="-1.421" spread="2.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: CRP Change = Treatment + Baseline CRP.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.597</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.178</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.948</ci_lower_limit>
            <ci_upper_limit>-1.247</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.458</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.200</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.852</ci_lower_limit>
            <ci_upper_limit>-1.065</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CRP Through Week 52</title>
        <description>Higher CRP indicates greater disease activity.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CRP Through Week 52</title>
          <description>Higher CRP indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.055" spread="1.539"/>
                    <measurement group_id="O2" value="-1.411" spread="1.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.207" spread="1.839"/>
                    <measurement group_id="O2" value="-1.569" spread="1.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.532" spread="1.849"/>
                    <measurement group_id="O2" value="-1.458" spread="2.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.666" spread="1.828"/>
                    <measurement group_id="O2" value="-1.513" spread="2.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.660" spread="2.050"/>
                    <measurement group_id="O2" value="-1.660" spread="2.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.774" spread="2.022"/>
                    <measurement group_id="O2" value="-1.721" spread="2.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.803" spread="2.150"/>
                    <measurement group_id="O2" value="-1.721" spread="2.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.844" spread="2.214"/>
                    <measurement group_id="O2" value="-1.640" spread="2.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.832" spread="2.005"/>
                    <measurement group_id="O2" value="-1.696" spread="2.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.833" spread="2.156"/>
                    <measurement group_id="O2" value="-1.716" spread="2.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.815" spread="1.948"/>
                    <measurement group_id="O2" value="-1.725" spread="2.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.771" spread="2.189"/>
                    <measurement group_id="O2" value="-1.751" spread="2.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.841" spread="2.102"/>
                    <measurement group_id="O2" value="-1.912" spread="1.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.545" spread="2.315"/>
                    <measurement group_id="O2" value="-1.629" spread="2.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ESR at Week 12</title>
        <description>Higher ESR indicates greater disease activity.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ESR at Week 12</title>
          <description>Higher ESR indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="19.71"/>
                    <measurement group_id="O2" value="-18.90" spread="19.85"/>
                    <measurement group_id="O3" value="-22.17" spread="22.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: ESR Change = Treatment + Baseline ESR.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-17.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.61</ci_lower_limit>
            <ci_upper_limit>-14.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: ESR Change = Treatment + Baseline ESR.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-20.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.67</ci_lower_limit>
            <ci_upper_limit>-16.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ESR Through Week 52</title>
        <description>Higher ESR indicates greater disease activity.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ESR Through Week 52</title>
          <description>Higher ESR indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>mm/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.09" spread="14.34"/>
                    <measurement group_id="O2" value="-16.59" spread="16.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.96" spread="18.73"/>
                    <measurement group_id="O2" value="-21.10" spread="20.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.14" spread="19.81"/>
                    <measurement group_id="O2" value="-22.92" spread="22.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.42" spread="19.70"/>
                    <measurement group_id="O2" value="-24.29" spread="23.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.22" spread="20.78"/>
                    <measurement group_id="O2" value="-26.20" spread="24.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.35" spread="22.48"/>
                    <measurement group_id="O2" value="-27.36" spread="23.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="158"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.03" spread="23.70"/>
                    <measurement group_id="O2" value="-27.88" spread="24.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.92" spread="23.85"/>
                    <measurement group_id="O2" value="-27.21" spread="24.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.95" spread="22.68"/>
                    <measurement group_id="O2" value="-27.25" spread="25.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.86" spread="24.41"/>
                    <measurement group_id="O2" value="-27.74" spread="24.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.13" spread="22.73"/>
                    <measurement group_id="O2" value="-27.99" spread="23.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.63" spread="24.72"/>
                    <measurement group_id="O2" value="-27.83" spread="23.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.86" spread="23.60"/>
                    <measurement group_id="O2" value="-29.12" spread="23.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.00" spread="24.49"/>
                    <measurement group_id="O2" value="-26.11" spread="25.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a European League Against Rheumatism (EULAR) Good Response Using DAS28-CRP at Week 12</title>
        <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a European League Against Rheumatism (EULAR) Good Response Using DAS28-CRP at Week 12</title>
          <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="43.0"/>
                    <measurement group_id="O3" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>33.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.7</ci_lower_limit>
            <ci_upper_limit>42.2</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>45.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.2</ci_lower_limit>
            <ci_upper_limit>54.8</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a EULAR Good Response Using DAS28-CRP Through Week 52</title>
        <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a EULAR Good Response Using DAS28-CRP Through Week 52</title>
          <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1"/>
                    <measurement group_id="O2" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1"/>
                    <measurement group_id="O2" value="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3"/>
                    <measurement group_id="O2" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8"/>
                    <measurement group_id="O2" value="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6"/>
                    <measurement group_id="O2" value="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0"/>
                    <measurement group_id="O2" value="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5"/>
                    <measurement group_id="O2" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP at Week 12</title>
        <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP at Week 12</title>
          <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="77.9"/>
                    <measurement group_id="O3" value="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>42.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.3</ci_lower_limit>
            <ci_upper_limit>52.5</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>49.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>39.7</ci_lower_limit>
            <ci_upper_limit>58.9</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP Through Week 52</title>
        <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP Through Week 52</title>
          <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                    <measurement group_id="O2" value="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3"/>
                    <measurement group_id="O2" value="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6"/>
                    <measurement group_id="O2" value="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4"/>
                    <measurement group_id="O2" value="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1"/>
                    <measurement group_id="O2" value="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0"/>
                    <measurement group_id="O2" value="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8"/>
                    <measurement group_id="O2" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8"/>
                    <measurement group_id="O2" value="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3"/>
                    <measurement group_id="O2" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2"/>
                    <measurement group_id="O2" value="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4"/>
                    <measurement group_id="O2" value="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a EULAR Good Response Using DAS28-ESR at Week 12</title>
        <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in the outcome measure.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a EULAR Good Response Using DAS28-ESR at Week 12</title>
          <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in the outcome measure.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="23.8"/>
                    <measurement group_id="O3" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <method_desc>No multiplicity adjustment.</method_desc>
            <param_type>Percent Difference</param_type>
            <param_value>19.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.1</ci_lower_limit>
            <ci_upper_limit>27.3</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>30.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.0</ci_lower_limit>
            <ci_upper_limit>38.7</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a EULAR Good Response Using DAS28-ESR Through Week 52</title>
        <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a EULAR Good Response Using DAS28-ESR Through Week 52</title>
          <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good response have been reported in this outcome measure.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3"/>
                    <measurement group_id="O2" value="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6"/>
                    <measurement group_id="O2" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6"/>
                    <measurement group_id="O2" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8"/>
                    <measurement group_id="O2" value="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                    <measurement group_id="O2" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a EULAR Good or Moderate Response Using DAS28-ESR at Week 12</title>
        <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a EULAR Good or Moderate Response Using DAS28-ESR at Week 12</title>
          <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="74.4"/>
                    <measurement group_id="O3" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>42.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.3</ci_lower_limit>
            <ci_upper_limit>52.6</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>47.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>37.1</ci_lower_limit>
            <ci_upper_limit>56.9</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a EULAR Good or Moderate Response Using DAS28-ESR Through Week 52</title>
        <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a EULAR Good or Moderate Response Using DAS28-ESR Through Week 52</title>
          <description>The Disease Activity Score Based on 28-joints Count based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline &gt;1.2 with DAS28 =&lt; 3.2; moderate responders: change from baseline &gt;1.2 with DAS28 &gt;3.2 to =&lt;5.1 or change from baseline &gt;0.6 to =&lt;1.2 with DAS28 =&lt;5.1; non-responders: change from baseline =&lt; 0.6 or change from baseline &gt;0.6 and =&lt;1.2 with DAS28 &gt;5.1. Percentage of participants with good or moderate response have been reported in this outcome measure.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7"/>
                    <measurement group_id="O2" value="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3"/>
                    <measurement group_id="O2" value="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6"/>
                    <measurement group_id="O2" value="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0"/>
                    <measurement group_id="O2" value="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4"/>
                    <measurement group_id="O2" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="152"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6"/>
                    <measurement group_id="O2" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="147"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6"/>
                    <measurement group_id="O2" value="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0"/>
                    <measurement group_id="O2" value="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR / EULAR Remission at Week 12</title>
        <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤1, CRP ≤1 mg/dL, and participant's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR / EULAR Remission at Week 12</title>
          <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤1, CRP ≤1 mg/dL, and participant's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>9.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.1</ci_lower_limit>
            <ci_upper_limit>14.6</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR / EULAR Remission Through Week 52</title>
        <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤1, CRP ≤1 mg/dL, and participant's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR / EULAR Remission Through Week 52</title>
          <description>ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤1, CRP ≤1 mg/dL, and participant's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Remission &lt;=3.3 at Week 12</title>
        <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
        <time_frame>Week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Remission &lt;=3.3 at Week 12</title>
          <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="7.0"/>
                    <measurement group_id="O3" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>No multiplicity adjustment.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>6.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>13.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.5</ci_lower_limit>
            <ci_upper_limit>19.4</ci_upper_limit>
            <estimate_desc>CI was based on normal approximation to the binomial distribution (continuity corrected).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SDAI Remission Score &lt;=3.3 Through Week 52</title>
        <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SDAI Remission Score &lt;=3.3 Through Week 52</title>
          <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description. SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5"/>
                    <measurement group_id="O2" value="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                    <measurement group_id="O2" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3"/>
                    <measurement group_id="O2" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                    <measurement group_id="O2" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDAI Score at Week 12</title>
        <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description: SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDAI Score at Week 12</title>
          <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description: SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.90" spread="12.32"/>
                    <measurement group_id="O2" value="-15.66" spread="12.69"/>
                    <measurement group_id="O3" value="-19.57" spread="13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SDAI Change = Treatment + Baseline SDAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.84</ci_lower_limit>
            <ci_upper_limit>-8.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SDAI Change = Treatment + Baseline SDAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-14.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.35</ci_lower_limit>
            <ci_upper_limit>-11.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDAI Score Through Week 52</title>
        <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description: SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDAI Score Through Week 52</title>
          <description>SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to description: SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.02" spread="8.23"/>
                    <measurement group_id="O2" value="-13.79" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.60" spread="10.40"/>
                    <measurement group_id="O2" value="-18.36" spread="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.94" spread="12.59"/>
                    <measurement group_id="O2" value="-20.08" spread="13.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.75" spread="11.58"/>
                    <measurement group_id="O2" value="-22.21" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.24" spread="11.89"/>
                    <measurement group_id="O2" value="-23.03" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.62" spread="11.64"/>
                    <measurement group_id="O2" value="-24.68" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.89" spread="11.54"/>
                    <measurement group_id="O2" value="-24.57" spread="12.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.61" spread="11.15"/>
                    <measurement group_id="O2" value="-25.38" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.89" spread="11.10"/>
                    <measurement group_id="O2" value="-25.55" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.55" spread="11.20"/>
                    <measurement group_id="O2" value="-26.14" spread="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.55" spread="11.17"/>
                    <measurement group_id="O2" value="-26.44" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.23" spread="11.30"/>
                    <measurement group_id="O2" value="-26.50" spread="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.67" spread="11.91"/>
                    <measurement group_id="O2" value="-26.63" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.48" spread="13.42"/>
                    <measurement group_id="O2" value="-24.72" spread="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PGA at Week 12</title>
        <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PGA at Week 12</title>
          <description>The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.88" spread="21.46"/>
                    <measurement group_id="O2" value="-28.83" spread="22.21"/>
                    <measurement group_id="O3" value="-35.96" spread="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: PGA (100 mm VAS) Change = Treatment + Baseline PGA (100 mm VAS).</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-17.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.11</ci_lower_limit>
            <ci_upper_limit>-13.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: PGA (100 mm VAS) Change = Treatment + Baseline PGA (100 mm VAS).</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-24.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.66</ci_lower_limit>
            <ci_upper_limit>-19.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PGA Through Week 52</title>
        <description>The investigator assessed the participants disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only Peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PGA Through Week 52</title>
          <description>The investigator assessed the participants disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only Peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.36" spread="17.10"/>
                    <measurement group_id="O2" value="-22.94" spread="19.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.79" spread="19.59"/>
                    <measurement group_id="O2" value="-31.54" spread="22.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.07" spread="22.22"/>
                    <measurement group_id="O2" value="-36.55" spread="24.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.60" spread="21.27"/>
                    <measurement group_id="O2" value="-38.86" spread="23.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.18" spread="21.87"/>
                    <measurement group_id="O2" value="-41.44" spread="22.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.13" spread="21.71"/>
                    <measurement group_id="O2" value="-43.67" spread="21.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.72" spread="22.45"/>
                    <measurement group_id="O2" value="-42.43" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.04" spread="20.82"/>
                    <measurement group_id="O2" value="-43.96" spread="21.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.35" spread="21.25"/>
                    <measurement group_id="O2" value="-44.37" spread="21.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.04" spread="22.33"/>
                    <measurement group_id="O2" value="-44.32" spread="21.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.47" spread="22.73"/>
                    <measurement group_id="O2" value="-46.00" spread="21.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.55" spread="23.23"/>
                    <measurement group_id="O2" value="-45.84" spread="21.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.49" spread="23.75"/>
                    <measurement group_id="O2" value="-45.46" spread="23.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.41" spread="25.07"/>
                    <measurement group_id="O2" value="-43.33" spread="24.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGA at Week 12</title>
        <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGA at Week 12</title>
          <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.11" spread="23.05"/>
                    <measurement group_id="O2" value="-21.09" spread="23.63"/>
                    <measurement group_id="O3" value="-26.57" spread="25.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SGA (100 mm VAS) Change = Treatment + Baseline SGA (100 mm VAS)</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-16.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.09</ci_lower_limit>
            <ci_upper_limit>-12.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SGA (100 mm VAS) Change = Treatment + Baseline SGA (100 mm VAS).</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-20.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.07</ci_lower_limit>
            <ci_upper_limit>-15.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGA Through Week 52</title>
        <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only Peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGA Through Week 52</title>
          <description>The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only Peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.80" spread="19.47"/>
                    <measurement group_id="O2" value="-17.59" spread="20.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.11" spread="23.22"/>
                    <measurement group_id="O2" value="-24.97" spread="22.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.59" spread="23.43"/>
                    <measurement group_id="O2" value="-27.40" spread="24.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.20" spread="24.41"/>
                    <measurement group_id="O2" value="-30.14" spread="24.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.94" spread="25.49"/>
                    <measurement group_id="O2" value="-31.20" spread="25.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.00" spread="25.51"/>
                    <measurement group_id="O2" value="-32.79" spread="25.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.04" spread="24.96"/>
                    <measurement group_id="O2" value="-34.25" spread="25.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.92" spread="24.99"/>
                    <measurement group_id="O2" value="-33.46" spread="24.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.38" spread="25.34"/>
                    <measurement group_id="O2" value="-34.01" spread="23.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.80" spread="25.85"/>
                    <measurement group_id="O2" value="-34.24" spread="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.49" spread="25.86"/>
                    <measurement group_id="O2" value="-35.31" spread="25.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.69" spread="26.18"/>
                    <measurement group_id="O2" value="-35.33" spread="23.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.18" spread="27.83"/>
                    <measurement group_id="O2" value="-36.16" spread="25.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.34" spread="28.78"/>
                    <measurement group_id="O2" value="-34.05" spread="26.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGAP at Week 12</title>
        <description>The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicated greater activity pain.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGAP at Week 12</title>
          <description>The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicated greater activity pain.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.64" spread="25.22"/>
                    <measurement group_id="O2" value="-21.09" spread="27.04"/>
                    <measurement group_id="O3" value="-26.87" spread="26.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SGAP (100 mm VAS) Change = Treatment + Baseline SGAP (100 mm VAS).</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-17.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.00</ci_lower_limit>
            <ci_upper_limit>-12.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SGAP (100 mm VAS) Change = Treatment + Baseline SGAP (100 mm VAS).</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-20.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.80</ci_lower_limit>
            <ci_upper_limit>-15.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGAP Through Week 52</title>
        <description>The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicated greater activity pain.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only Peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGAP Through Week 52</title>
          <description>The participant assessed his/her own pain severity on a visual analog scale (VAS) of 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicated greater activity pain.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only Peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.94" spread="20.75"/>
                    <measurement group_id="O2" value="-16.18" spread="22.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.10" spread="25.81"/>
                    <measurement group_id="O2" value="-24.98" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.27" spread="27.03"/>
                    <measurement group_id="O2" value="-27.81" spread="26.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.03" spread="26.09"/>
                    <measurement group_id="O2" value="-28.42" spread="26.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.57" spread="28.52"/>
                    <measurement group_id="O2" value="-30.63" spread="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.34" spread="27.54"/>
                    <measurement group_id="O2" value="-32.72" spread="26.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.54" spread="27.24"/>
                    <measurement group_id="O2" value="-34.18" spread="25.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.32" spread="25.76"/>
                    <measurement group_id="O2" value="-33.74" spread="25.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.95" spread="26.17"/>
                    <measurement group_id="O2" value="-32.66" spread="26.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.17" spread="26.81"/>
                    <measurement group_id="O2" value="-34.07" spread="25.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.73" spread="26.67"/>
                    <measurement group_id="O2" value="-34.88" spread="25.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.60" spread="25.87"/>
                    <measurement group_id="O2" value="-35.07" spread="25.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.34" spread="26.98"/>
                    <measurement group_id="O2" value="-35.00" spread="27.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.94" spread="28.63"/>
                    <measurement group_id="O2" value="-32.68" spread="28.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Withdrew Due to Lack of Efficacy</title>
        <description>Participants who discontinued due to lack of efficacy have been reported.</description>
        <time_frame>Up to week 52</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Withdrew Due to Lack of Efficacy</title>
          <description>Participants who discontinued due to lack of efficacy have been reported.</description>
          <population>FAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI at Week 12</title>
        <description>Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI at Week 12</title>
          <description>Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.47"/>
                    <measurement group_id="O2" value="-0.22" spread="0.44"/>
                    <measurement group_id="O3" value="-0.37" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: HAQ-DI Change = Treatment + Baseline HAQ-DI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: HAQ-DI Change = Treatment + Baseline HAQ-DI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI Through Week 52</title>
        <description>Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI Through Week 52</title>
          <description>Participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.30"/>
                    <measurement group_id="O2" value="-0.21" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.41"/>
                    <measurement group_id="O2" value="-0.32" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.44"/>
                    <measurement group_id="O2" value="-0.38" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.46"/>
                    <measurement group_id="O2" value="-0.41" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="164"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.48"/>
                    <measurement group_id="O2" value="-0.47" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.50"/>
                    <measurement group_id="O2" value="-0.48" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.51"/>
                    <measurement group_id="O2" value="-0.51" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.51"/>
                    <measurement group_id="O2" value="-0.53" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.50"/>
                    <measurement group_id="O2" value="-0.53" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.50"/>
                    <measurement group_id="O2" value="-0.56" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.50"/>
                    <measurement group_id="O2" value="-0.54" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.49"/>
                    <measurement group_id="O2" value="-0.56" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.51"/>
                    <measurement group_id="O2" value="-0.56" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.55"/>
                    <measurement group_id="O2" value="-0.51" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form Health Survey - 36 Questions, Version 2 (SF-36v2) Physical Component Summary Score at Week 12</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form Health Survey - 36 Questions, Version 2 (SF-36v2) Physical Component Summary Score at Week 12</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="12.08"/>
                    <measurement group_id="O2" value="6.60" spread="11.06"/>
                    <measurement group_id="O3" value="9.02" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SF36-v2 Change = Treatment + Baseline SF36-v2.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.09</ci_lower_limit>
            <ci_upper_limit>8.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SF36-v2 Change = Treatment + Baseline SF36-v2.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.36</ci_lower_limit>
            <ci_upper_limit>10.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Physical Component Summary Score Through Week 52</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Physical Component Summary Score Through Week 52</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" spread="8.91"/>
                    <measurement group_id="O2" value="5.77" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="10.82"/>
                    <measurement group_id="O2" value="7.91" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.68" spread="11.08"/>
                    <measurement group_id="O2" value="9.32" spread="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89" spread="11.86"/>
                    <measurement group_id="O2" value="12.44" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27" spread="12.05"/>
                    <measurement group_id="O2" value="12.45" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" spread="12.81"/>
                    <measurement group_id="O2" value="11.51" spread="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Mental Component Summary Score at Week 12</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Mental Component Summary Score at Week 12</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="8.27"/>
                    <measurement group_id="O2" value="3.28" spread="7.47"/>
                    <measurement group_id="O3" value="2.50" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SF36-v2 Change = Treatment + Baseline SF36-v2.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>4.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SF36-v2 Change = Treatment + Baseline SF36-v2.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>3.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Mental Component Summary Score Through Week 52</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Mental Component Summary Score Through Week 52</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="7.02"/>
                    <measurement group_id="O2" value="1.33" spread="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="7.39"/>
                    <measurement group_id="O2" value="2.44" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="7.47"/>
                    <measurement group_id="O2" value="2.67" spread="8.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="8.55"/>
                    <measurement group_id="O2" value="3.12" spread="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="9.10"/>
                    <measurement group_id="O2" value="1.85" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="8.89"/>
                    <measurement group_id="O2" value="1.67" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Role/Social Component Summary Score at Week 12</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Role/Social Component Summary Score at Week 12</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="16.69"/>
                    <measurement group_id="O2" value="2.30" spread="13.92"/>
                    <measurement group_id="O3" value="3.90" spread="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.099</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SF36-v2 Change = Treatment + Baseline SF36-v2.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>5.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: SF36-v2 Change = Treatment + Baseline SF36-v2.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.53</ci_lower_limit>
            <ci_upper_limit>6.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36v2 Role/Social Component Summary Score Through Week 52</title>
        <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36v2 Role/Social Component Summary Score Through Week 52</title>
          <description>The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="11.51"/>
                    <measurement group_id="O2" value="1.70" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="13.79"/>
                    <measurement group_id="O2" value="3.30" spread="13.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="14.05"/>
                    <measurement group_id="O2" value="3.92" spread="13.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="158"/>
                    <count group_id="O2" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="14.92"/>
                    <measurement group_id="O2" value="4.81" spread="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="147"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="15.31"/>
                    <measurement group_id="O2" value="7.17" spread="14.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" spread="14.85"/>
                    <measurement group_id="O2" value="5.88" spread="14.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Percent Work Time Missed at Week 12</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent work time missed due to problem was calculated as Q2/(Q2+Q4). Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Percent Work Time Missed at Week 12</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent work time missed due to problem was calculated as Q2/(Q2+Q4). Negative values indicate improvement from baseline.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percent work time missed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="17.77"/>
                    <measurement group_id="O2" value="0.36" spread="18.15"/>
                    <measurement group_id="O3" value="-1.46" spread="15.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.879</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: WPAI Change = Treatment + Baseline WPAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.16</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.377</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: WPAI Change = Treatment + Baseline WPAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.86</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Work Time Missed Through Week 52</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent work time missed due to problem was calculated as Q2/(Q2+Q4). Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Work Time Missed Through Week 52</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent work time missed due to problem was calculated as Q2/(Q2+Q4). Negative values indicate improvement from baseline.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percent work time missed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="16.50"/>
                    <measurement group_id="O2" value="0.02" spread="16.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="15.72"/>
                    <measurement group_id="O2" value="-1.73" spread="16.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="14.69"/>
                    <measurement group_id="O2" value="-1.97" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="19.15"/>
                    <measurement group_id="O2" value="-3.49" spread="13.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="12.14"/>
                    <measurement group_id="O2" value="-1.66" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="14.68"/>
                    <measurement group_id="O2" value="-1.66" spread="20.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Impairment While Working at Week 12</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent impairment while working due to problem was calculated as Q5/10. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Impairment While Working at Week 12</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent impairment while working due to problem was calculated as Q5/10. Negative values indicate improvement from baseline.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percent work impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="27.78"/>
                    <measurement group_id="O2" value="-11.71" spread="25.62"/>
                    <measurement group_id="O3" value="-15.96" spread="28.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: WPAI Change = Treatment + Baseline WPAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.54</ci_lower_limit>
            <ci_upper_limit>-2.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: WPAI Change = Treatment + Baseline WPAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-14.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.24</ci_lower_limit>
            <ci_upper_limit>-7.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Impairment While Working Through Week 52</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent impairment while working due to problem was calculates as Q5/10. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Impairment While Working Through Week 52</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent impairment while working due to problem was calculates as Q5/10. Negative values indicate improvement from baseline.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percent work impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.00" spread="22.39"/>
                    <measurement group_id="O2" value="-6.56" spread="29.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.50" spread="24.93"/>
                    <measurement group_id="O2" value="-13.98" spread="26.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.97" spread="26.33"/>
                    <measurement group_id="O2" value="-16.29" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.00" spread="25.27"/>
                    <measurement group_id="O2" value="-21.40" spread="25.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.97" spread="29.90"/>
                    <measurement group_id="O2" value="-22.41" spread="28.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.35" spread="29.10"/>
                    <measurement group_id="O2" value="-20.43" spread="28.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent Overall Work Impairment at Week 12</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent overall work impairment due to problem was calculated as Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)]. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent Overall Work Impairment at Week 12</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent overall work impairment due to problem was calculated as Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)]. Negative values indicate improvement from baseline.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percent overall work impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" spread="28.56"/>
                    <measurement group_id="O2" value="-11.58" spread="26.22"/>
                    <measurement group_id="O3" value="-16.91" spread="29.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: WPAI Change = Treatment + Baseline WPAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.60</ci_lower_limit>
            <ci_upper_limit>-2.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: WPAI Change = Treatment + Baseline WPAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-14.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.92</ci_lower_limit>
            <ci_upper_limit>-7.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Overall Work Impairment Through Week 52</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent overall work impairment due to problem was calculated as Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)]. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Overall Work Impairment Through Week 52</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent overall work impairment due to problem was calculated as Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)]. Negative values indicate improvement from baseline.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percent overall work impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.61" spread="22.36"/>
                    <measurement group_id="O2" value="-7.51" spread="30.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.13" spread="25.07"/>
                    <measurement group_id="O2" value="-14.67" spread="26.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.15" spread="26.81"/>
                    <measurement group_id="O2" value="-17.15" spread="28.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.76" spread="25.78"/>
                    <measurement group_id="O2" value="-22.49" spread="26.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.48" spread="30.96"/>
                    <measurement group_id="O2" value="-23.40" spread="29.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.43" spread="30.01"/>
                    <measurement group_id="O2" value="-21.59" spread="29.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Activity Impairment at Week 12</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent activity impairment due to problem was calculated as Q6/10. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline and week 12/ET</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Activity Impairment at Week 12</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent activity impairment due to problem was calculated as Q6/10. Negative values indicate improvement from baseline.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. LOCF was used for missing imputations.</population>
          <units>percent activity impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="28.19"/>
                    <measurement group_id="O2" value="-13.98" spread="27.17"/>
                    <measurement group_id="O3" value="-19.35" spread="24.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: WPAI Change = Treatment + Baseline WPAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-13.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.23</ci_lower_limit>
            <ci_upper_limit>-8.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment Difference vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA Model: WPAI Change = Treatment + Baseline WPAI.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-17.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.57</ci_lower_limit>
            <ci_upper_limit>-12.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WPAI Percent Activity Impairment Through Week 52</title>
        <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent activity impairment due to problem was calculated as Q6/10. Negative values indicate improvement from baseline.</description>
        <time_frame>Baseline, weeks 4, 8, 12, 28, 52 and EOT</time_frame>
        <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WPAI Percent Activity Impairment Through Week 52</title>
          <description>WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicated greater activity impairment. The scores were multiplied by 100 to express in percentages. Percent activity impairment due to problem was calculated as Q6/10. Negative values indicate improvement from baseline.</description>
          <population>FAS. Here, Number of participants analyzed signifies participants with available data. Only peficitinib 100 mg and 150 mg arms are analyzed for this outcome measure, as planned.</population>
          <units>percent activity impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.23" spread="22.81"/>
                    <measurement group_id="O2" value="-10.65" spread="22.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                    <count group_id="O2" value="164"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.07" spread="26.12"/>
                    <measurement group_id="O2" value="-17.44" spread="24.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="167"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.71" spread="27.30"/>
                    <measurement group_id="O2" value="-19.88" spread="24.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.17" spread="27.25"/>
                    <measurement group_id="O2" value="-26.99" spread="24.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.10" spread="31.72"/>
                    <measurement group_id="O2" value="-26.71" spread="24.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.58" spread="31.67"/>
                    <measurement group_id="O2" value="-23.47" spread="25.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) During the First 12 Weeks</title>
        <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
        <time_frame>Week 0 to week 12</time_frame>
        <population>SAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) During the First 12 Weeks</title>
          <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
          <population>SAF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ Grade 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to permanent discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related AE leading to permanent discont.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs From Week 12 to Week 28</title>
        <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on NCI-CTCAE, AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE</description>
        <time_frame>Week 12 to week 28</time_frame>
        <population>SAF. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matching to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matching to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs From Week 12 to Week 28</title>
          <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on NCI-CTCAE, AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE</description>
          <population>SAF. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="165"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ Grade 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to permanent discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-Related TEAE leading to permanent dicont.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAEs From Week 28 to Week 52</title>
        <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
        <time_frame>Week 28 to week 52, plus 28 days after the week 52 visit for participants who did not enroll in the extension study</time_frame>
        <population>SAF. Here, Number of participants analyzed signifies participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Peficitinib 100 mg</title>
            <description>Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Peficitinib 150 mg</title>
            <description>Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo / Peficitinib 100 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo / Peficitinib 150 mg at Week 12</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 to week 52.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Peficitinib 100 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Peficitinib 150 mg at Week 28</title>
            <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 150 mg tablet of peficitinib orally once daily in combination with MTX from week 28 to week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs From Week 28 to Week 52</title>
          <description>TEAEs were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), AEs were graded as grade 1=mild; grade 2=moderate: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.</description>
          <population>SAF. Here, Number of participants analyzed signifies participants with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ Grade 3 TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to permanent discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 0 to week 12, week 12 to week 28, and week 28 to week 52 plus 28 days after the week 52 visit for participants who did not enroll in the extension study.</time_frame>
      <desc>SAF.</desc>
      <group_list>
        <group group_id="E1">
          <title>Week 0 to Week 12: Placebo</title>
          <description>Participants received placebo matched to peficitinib orally once daily in combination with MTX until week 12.</description>
        </group>
        <group group_id="E2">
          <title>Week 0 to Week 12: Peficitinib 100 mg</title>
          <description>Participants received 100 mg tablet of Peficitinib orally once daily in combination with MTX for a period of 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Week 0 to Week 12: Peficitinib 150 mg</title>
          <description>Participants received 150 mg tablet of Peficitinib orally once daily in combination with MTX for a period of 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Week 12 to Week 28: Placebo</title>
          <description>Participants received placebo matched to peficitinib orally once daily in combination with MTX until week 12 and from week 12 to 28.</description>
        </group>
        <group group_id="E5">
          <title>Week 12 to Week 28: Peficitinib 100 mg</title>
          <description>Participants received 100 mg tablet of Peficitinib orally once daily in combination with MTX until week 12 and from week 12 to 28.</description>
        </group>
        <group group_id="E6">
          <title>Week 12 to Week 28: Peficitinib 150 mg</title>
          <description>Participants received 150 mg tablet of Peficitinib orally once daily in combination with MTX until week 12 and from week 12 to 28.</description>
        </group>
        <group group_id="E7">
          <title>Week 12 to Week 28: Placebo / Peficitinib 100 mg at Week 12</title>
          <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet orally once daily in combination with MTX from week 12 to week 28.</description>
        </group>
        <group group_id="E8">
          <title>Week 12 to Week 28: Placebo / Peficitinib 150 mg at Week 12</title>
          <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet orally once daily in combination with MTX from week 12 to week 28.</description>
        </group>
        <group group_id="E9">
          <title>Week 28 to Week 52: Peficitinib 100 mg</title>
          <description>Participants received 100 mg tablet of Peficitinib orally once daily in combination with MTX until week 28 and from week 28 to 52.</description>
        </group>
        <group group_id="E10">
          <title>Week 28 to Week 52: Peficitinib 150 mg</title>
          <description>Participants received 150 mg tablet of Peficitinib orally once daily in combination with MTX until week 28 and from week 28 to 52.</description>
        </group>
        <group group_id="E11">
          <title>Week 28 to Week 52: Placebo / Peficitinib 100 mg at Week 12</title>
          <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 12 were switched to receive 100 mg tablet orally once daily in combination with MTX from week 12 to week 52.</description>
        </group>
        <group group_id="E12">
          <title>Week 28 to Week 52: Placebo / Peficitinib 150 mg at Week 12</title>
          <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 12 were switched to receive 150 mg tablet orally once daily in combination with MTX from week 12 to week 52.</description>
        </group>
        <group group_id="E13">
          <title>Week 28 to Week 52: Placebo / Peficitinib 100 mg at Week 28</title>
          <description>Participants who received placebo matched to peficitinib 100 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet orally once daily in combination with MTX from week 28 to week 52.</description>
        </group>
        <group group_id="E14">
          <title>Week 28 to Week 52: Placebo / Peficitinib 150 mg at Week 28</title>
          <description>Participants who received placebo matched to peficitinib 150 mg orally once daily in combination with MTX until week 28 were switched to receive 100 mg tablet orally once daily in combination with MTX from week 28 to week 52.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="158"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pneumonia cryptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brachial plexus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Borderline ovarian tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="174"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="56" subjects_at_risk="167"/>
                <counts group_id="E6" subjects_affected="60" subjects_at_risk="165"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E9" subjects_affected="63" subjects_at_risk="158"/>
                <counts group_id="E10" subjects_affected="73" subjects_at_risk="158"/>
                <counts group_id="E11" subjects_affected="16" subjects_at_risk="36"/>
                <counts group_id="E12" subjects_affected="22" subjects_at_risk="36"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E14" subjects_affected="20" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="158"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" events="5" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="158"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E11" events="5" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="170"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="174"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="174"/>
                <counts group_id="E4" events="14" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E5" events="24" subjects_affected="20" subjects_at_risk="167"/>
                <counts group_id="E6" events="22" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" events="27" subjects_affected="25" subjects_at_risk="158"/>
                <counts group_id="E10" events="40" subjects_affected="38" subjects_at_risk="158"/>
                <counts group_id="E11" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E12" events="6" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E13" events="6" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E14" events="8" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E10" events="6" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="158"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E13" events="4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E10" events="10" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="158"/>
                <counts group_id="E10" events="6" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure</name_or_title>
      <organization>Astellas Pharma Inc.</organization>
      <phone>+81-3-3244-6500 Japanese only</phone>
      <email>Astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

